Annual Meeting News

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and its research collaborators today presented results of the largest study to date evaluating circulating tumor DNA (ctDNA) in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal™ test to stratify the risk of disease recurrence and overall survival, and thus inform treatment decisions after surgery. Data from the phase III trial of FOLFOX-based adjuvant...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall survival (OS) analysis of the Phase III INAVO120 study. These data showed ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, reduced the risk of death by more than 30% compared with palbociclib and fulvestrant alone. This represents a statistically significant and clinically meaningful improvem...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care Keytruda plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). Trodelvy when given in combination with Keytruda resulted in a median progression-free survival (PFS) of 11.2 mo...

SAN DIEGO--(BUSINESS WIRE)--Cofactor Genomics announced the latest validation results for OncoPrism®, Cofactor’s breakthrough RNA-based diagnostic approach at the RNA Society’s 30th Annual Meeting. The talk, presented by Dr. Kevin Flanagan (Cofactor’s VP of Translational Science), “Bringing Precision Medicine to Cancer Immunotherapy with a Robust RNA Diagnostic Platform”, highlighted OncoPrism’s dramatic improvement in the prediction of patient responses to cancer immunotherapies relative to ot...

SAN FRANCISCO--(BUSINESS WIRE)--Planet Labs PBC (NYSE: PL), a leading provider of daily data and insights about Earth, today announced that its board of directors has nominated Gary B. Smith, President and CEO of Ciena, as a Class I director for election at the upcoming Annual Meeting. "Gary’s expansive career and leadership across technology, operations and sales is invaluable to Planet’s continued growth as a data platform company," said Will Marshall, Co-Founder, Chief Executive Officer and...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the presentation of two new abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including an oral presentation selected for Best of ASCO 2025, an honor reserved for studies with the greatest potential to shape the future of cancer care. The featured oral presentation showcases the first validated MMAI algo...

BOSTON--(BUSINESS WIRE)--Ontada, a leader in real-world oncology data and insights, is proud to present its latest research findings in a pivotal oral presentation at ASCO....

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic colorectal cancer (mCRC)—a tumor type traditionally resistant to immunotherapy and representing approxim...

CHICAGO--(BUSINESS WIRE)--Onc.AI, a digital health company developing AI-powered oncology clinical management solutions, today announced that new validation study results from research collaborations with Pfizer, Baylor Scott & White and the University of Rochester Medical Center will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30–June 3, 2025, in Chicago, IL. Onc.AI’s poster presentation showcases its FDA-breakthrough designated deep learn...

MONTREAL--(BUSINESS WIRE)--Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the "Corporation"), is pleased to announce Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory firm, recommended the Corporation’s shareholders vote FOR all of the resolutions that will be put forth at the Corporation’s annual meeting of shareholders (the “Meeting”), scheduled for June 17, 2025 at 10:00 a.m. (Eastern Time). Dynacor is also providing corporate updates below to apprise shareho...